Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1651 to 1665 of 8938 results

  1. Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA927)

    Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

  2. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under (TA975)

    Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.

  3. Burosumab for treating X-linked hypophosphataemia in adults (TA993)

    Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.

  4. Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)

    Evidence-based recommendations on pembrolizumab (Keytruda) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults.

  5. Transvenous embolisation for treating cerebrospinal fluid-venous fistula associated with spontaneous intracranial hypotension

    In development Reference number: GID-IPG10318 Expected publication date:  25 March 2026

  6. Suspected Cancer: recognition and referral (update)

    In development Reference number: GID-NG10443 Expected publication date:  25 March 2026

  7. Percutaneous insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10404 Expected publication date:  25 March 2026

  8. Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock

    In development Reference number: GID-IPG10461 Expected publication date:  25 March 2026

  9. Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 26 February 2026.

  10. d-NAV for optimization of personal insulin management in adults with type 2 diabetes (MT696)

    Topic prioritisation

  11. CT hepatic arteriography for patients undergoing percutaneous ablation of primary or secondary liver tumours

    Topic prioritisation

  12. Wireless breast lesion localization using Savi Scout seed

    Topic prioritisation

  13. AHEAD implants for external ear prosthesis

    Topic prioritisation

  14. Intradiscal oxygen-ozone treatment of symptomatic lumbar disc herniation

    Topic prioritisation

  15. Insertion of Stoma Preservation Device

    Topic prioritisation